- Open Access
miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST
© Zhou et al.; licensee BioMed Central Ltd. 2014
- Received: 15 December 2013
- Accepted: 7 January 2014
- Published: 27 January 2014
miRNAs are involved in osteosarcoma (OS) chemoresistance, and TWIST reportedly enhances cisplatin-induced OS cell apoptosis by inhibiting multiple signaling pathways. In this study, we profiled miRNAs differentially expressed in chemoresistant OS, with a focus to identify miRNAs that regulate TWIST expression and OS chemoresistance.
OS patients who showed <90% tumor necrosis after neochemotherapy were defined as poor responders (chemoresistant), and those who showed ≥90% tumor necrosis were defined as good responders (control). miRNA microarray analysis was carried out with a discovery cohort (n = 12) of age-, sex- and tumor stage-matched chemoresistant and control OS patients.
Among the up-regulated miRNAs in chemoresistant OS samples, miR-33a was verified to down-regulate TWIST expression, which was supported by an inverse miRNA-33a/TWIST expression trend in the validation cohort (n = 70), target-sequence-specific inhibition of TWIST-3′ untranslated region-luciferase reporter activity by miR-33a, and alteration of TWIST expression by overexpression or inhibition of miR-33a in human OS cell lines. In Saos-2 cells treated with cisplatin, inhibition of miR-33a by antagomir-33a markedly increased cell apoptosis, which was enhanced by overexpression of TWIST. The apoptosis-inducing effect of TWIST overexpression was reversed by overexpression of miR-33a. In MG-63 cells, overexpression of miR-33a significantly decreased cisplatin-induced cell apoptosis, which was enhanced by knockdown of TWIST. Antagomir-33a significantly increased cisplatin-induced cell apoptosis, which was reversed by knockdown of TWIST.
We have demonstrated in this study that miR-33a is up-regulated in chemoresistant OS and that the miR-33a level is negatively correlated with the TWIST protein level in OS. Our in vitro data indicate that miR-33a promotes OS cell resistance to cisplatin by down-regulating TWIST; on the other hand, inhibition of miR-33a by antagomir-33a enhances cisplatin-induced apoptosis in OS cells by up-regulating TWIST expression. The findings suggest that inhibition of miR-33a/TWIST signaling could be a potential new strategy to enhance neoadjuvant chemotherapy for OS.
Osteosarcoma (OS) is the most frequent malignant bone tumor in children and adolescents, comprising 2.4% of all malignancies in pediatric patients . The 5-year survival rate of OS patients has significantly improved over the past decades to approximately 60-70% since the introduction of combinatorial chemotherapy . However, a significant proportion of OS patients still respond poorly to chemotherapy, and they have a risk of local relapse or distant metastasis even after curative resection of the primary tumor and intensive chemotherapy. Standard chemotherapy of OS is based on a combination of different drugs: neoadjuvant therapy with methotrexate, cisplatin, and doxorubicin followed by surgery and post-operative chemotherapy (methotrexate, cisplatin, doxorubicin, cyclophosphamide, and vincristine). Despite this, approximately 30% of patients relapse or develop metastasis . The lack of responsiveness to chemotherapy due to intrinsic or acquired chemoresistance is the major reason for poor survival and disease relapse of OS patients . Recently, novel molecular targeted drugs have emerged, but they have not been well established for the treatment of OS . In addition, the molecular mechanisms underlying OS chemoresistance remain largely obscure. Hence, identification of factors that contribute to OS chemoresistance and elucidation of the underlying mechanisms will be pivotal in the development of new therapeutic strategies.
TWIST, also known as TWIST1, belongs to the basic helix-loop-helix (bHLH) transcription factor family. During embryonic development, TWIST plays an essential role in specification of the mesoderm and differentiation of the mesoderm-derived tissues . Twist haploinsufficiency was shown to upset bone tissue in both mice and humans [7, 8]. In homogeneous cohort of OS patients, the TWIST gene was frequently deleted in the tumors at diagnosis, and its haploinsufficiency was significantly correlated with a poorer patient outcome [6, 9]. It has been reported that TWIST decreases OS cell survival against cisplatin by inhibiting β-catenin signaling and endothelin-1/endothelin A receptor signaling pathways [10, 11], suggesting that TWIST is an important negative regulator in the development of OS chemoresistance.
MicroRNAs (miRNAs) are noncoding small RNAs, usually 18–25 nucleotides in length, which repress translation and cleave mRNA by base-pairing to the 3′-untranslated region (UTR) of the target genes . Knowledge of individual miRNAs effecting developmental biology, cellular differentiation programs, and oncogenesis continues to grow . Differences in the miRNA expression profiles detected between cancer cells and their normal counterparts have revealed that miRNAs are involved in the pathogenesis of cancer . In addition, miRNAs may play multiple roles as tumor suppressors, oncogenes, or both in some cases . The biological properties of miRNAs may make them useful as diagnostic and prognostic tools as well as therapeutic targets in various cancers, including OS. A number of miRNAs reportedly are involved in OS tumorigenesis and chemoresistance .
In the present study, we screened for miRNAs regulating TWIST expression in human OS and explored their functional interaction in modulating human OS chemoresistance.
Characteristics of study cohorts
Chemoresistant OS (n=6)
Chemoresistant OS (n=35)
Gender n (%)
Tumor stage n (%)
Body mass index (kg/m2)
Tumor necrosis (%)
Cells lines, reagents and plasmid constructs
Saos-2 and MG-63 human OS cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA). Human Twist cDNA was subcloned into the pcDNA 3.1 expression vector . Twist (sc-38604-V) short hairpin RNA (shRNA) lentiviral particles, control shRNA lentiviral particles-A (sc-108080), and anti-TWIST (sc-81417) antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The DeadEnd™ Fluorometric TUNEL System was purchased from Promega (Madison, WI, USA). Superfect™ transfection reagent was purchased from Qiagen (Valencia, CA, USA). Dual-luciferase reporter assay system was purchased from Promega (Madison, WI, USA). Puromycin, cisplatin, and all chemicals of reagent grade were purchased from Sigma (St. Louis, MO, USA). The 3′-UTR of TWIST was amplified from genomic DNA using the following primers: 5′-GCGCCTCGAGCAGGCGGAGCCCCCCACCCCCTCA-3′ (forward) and 5′-GCGCGCGGCCGCGCAGAAAAATATACAAAGATATT-3′ (reverse). The TWIST-3′UTR-luciferase reporter was generated by inserting the TWIST 3′-UTR between XhoI and NotI restriction sites (underlined in the above primers) of the psiCheck2 vector (Promega) downstream of the renilla luciferase gene. PsiCheck2 vector (Promega) was used as a control vector. TWIST-mut33-luciferase reporter was generated by site-directed mutagenesis with the following primers: 5′-TTTATTGAGGACCCATGGTAACATATGAATAGATCCGGTGTCTAAATGC-3′ (forward) and 5′-GCATTTAGACACCGGATCTATTCATATGTTACCATGGGTCCTCAATAAA-3′ (reverse). The miRNA-33 anti-seed sequence was converted to NdeI restriction site (underlined in the primers). Antagomir-33a (427064-00hsa-miR-33amiRCURY LNA™ microRNA Power inhibitor) was purchased from Exiqon (Woburn, MA, USA). miRNAs potentially able to suppress TWIST expression were selected by using TargetScan prediction software (http://www.targetscan.org). The miR-Vecs (miRNA expressing vectors) and MSCV-hTR (control vector) constructs were made as previously described .
miRNA microarray analysis
Total RNA from OS tissues of the discovery cohort of patients was isolated using TRIzol reagent. The integrity of RNA was confirmed by agarose gel electrophoresis and its concentration determined by spectrophotometry. TaqMan Low Density miRNA Arrays (Applied Biosystems, Carlsbad, CA, USA) was used to assay the expression of human miRNAs by the manufacturer’s protocol. Manual inspection of all amplification plots was performed and miRNAs were excluded from the analysis if CT values were too high (>35, indicating that a miRNA expression is too low for accurate detection). Data analysis was performed using SDS 2.3 software (Applied Biosystems), which utilizes the delta-delta CT method .
Real-time quantitative reverse transcription PCR
Total RNA was prepared from OS tissues or cell lines using TRIzol reagent followed by purification with TURBO DNA-free System (Ambion, Austin, TX). The cDNAs were synthesized using SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Real-time quantitative PCR was performed using SYBR Green PCR master mix (Applied Biosystems) in a 7300 Real-time PCR System (Applied Biosystems). TaqMan microRNA assays (Applied Biosystems) that include RT primers and TaqMan probes were used to quantify the expression of mature miRNA-33a. The mean Ct was determined from triplicate PCRs. Gene expression was calculated relative to GAPDH. For measurement of TWIST mRNA, the following primers were used: for human TWIST, 5′-ACGAGCTGGACTCCAAGATG-3′ (forward) and 5′-CACGCCCTGTTTCTTTGAAT-3′ (reverse); for human GAPDH, 5′-GACTCATGACCACAGTCCATGC-3′ (forward) and 5′-AGAGGCAGGGATGATGTTCTG-3′ (reverse). The results were normalized against that of the GAPDH gene in the same sample. Each experiment was repeated for two times in triplicates.
Western blot analysis
Briefly, cells were dissolved in 250 μl of 2× SDS loading buffer (62.5 mM TrisHCl, pH 6.8, 2% SDS, 25% glycerol, 0.01% bromphenol blue, 5% 2-mercaptoethanol), and incubated at 95°C for 10 min. Equal amount of proteins for each sample were separated by 10% SDS-polyacrylamide gel and blotted onto a polyvinylidene difluoride microporous membrane (Millipore, Billerica, MA, USA). Membranes were incubated for 1 h with a 1/1000 dilution of primary antibody, and then washed and revealed using secondary antibodies with horseradish peroxidase conjugate (1/5000, 1 h). Peroxidase was revealed with a GE Healthcare ECL kit (Shanghai, China).
Transfection and lentiviral transduction
Plasmid constructs were transfected into cells using Superfect™ transfection reagent (Qiagen) according to the manufacture’s instructions. Pools of stable transfectants of TWIST were generated via selection with G418 (800 μg/ml) by the manufacturer’s protocol. Lentiviral transduction of TWIST-shRNA was performed and pools of stable transductants were generated via selection with puromycin (5 μg/ml).
MG-63 cells were transfected with luciferase reporter constructs using Superfect™ transfection reagent (Qiagen). Luciferase activity was measured 72 hours after transfection using the Dual-luciferase reporter assay system (Promega) following the manufacturer’s instructions. Experiments were conducted in triplicates and results were expressed as ratios between renilla and firefly luciferase counts.
Measurement of apoptosis by TUNEL (terminal deoxynucleotidyl transferase mediated nick-end labeling) assay
The TUNEL assay was performed using the DeadEnd™ Fluorometric TUNEL System by the manufacturer’s protocol (Promega). Cells were treated with cisplatin (15 nM) for 8 hours. Apoptotic cells exhibit a strong nuclear green fluorescence that could be detected using a standard fluorescein filter. All cells stained with DAPI exhibit a strong blue nuclear fluorescence. The slides were observed under fluorescence microscopy with relative apoptotic cells determined by counting TUNEL-positive cells in five random fields (magnification, ×100) for each sample.
Statistical analyses were performed with SPSS for Windows 10.0. All continuous variable values were expressed as Mean±SD. Comparison of means between two groups was performed with student t tests. Comparisons of means among multiple groups were performed with one-way ANOVA followed by post hoc pairwise comparisons using Tukey’s tests. A two-tailed p < 0.05 was considered statistically significant in this study.
miRNA expression profiling in chemoresistant and control OS
Up-regulated miRNAs in chemoresistant vs control osteosarcomas
Down-regulated miRNAs in chemoresistant vs control osteosarcomas
Screening of miRNAs able to regulate TWIST
To demonstrate a direct interaction between miR-33a and TWIST, the potential binding sequence for the miRNA within the 3′-UTR of TWIST, as predicted by TargetScan, was mutated to generate a TWIST-mut33-luciferase reporter (Figure 3B). MG-63 cells were co-transfected with miR-33a or miR-Vec control together with either TWIST-3′UTR-luciferase reporter or TWIST-mut33-luciferase reporter. The reduction of renilla luciferase activity caused by miRNA-33a was specifically abolished by the mutation of the corresponding anti-seed sequence (Figure 3C), suggesting that miR-33a could suppress TWIST expression by acting on its predicted sequence in the 3′-UTR.
Effect of overexpression and inhibition of miR-33a on TWIST expression in OS cells
Functional role of miR-33a in TWIST-inhibited OS cell survival against cisplatin
Chemoresistance is the major reason for poor survival of OS patients. Previous studies reported that TWIST could decrease OS cell survival against cisplatin by inhibiting multiple signaling pathways [10, 11], suggesting that TWIST is a pivotal negative regulator of OS chemoresistance. miRNAs reportedly are involved in the pathogenesis and chemoresistance of various cancers, including OS. In the present study, we profiled miRNAs differentially expressed in chemoresistant OS by microarray analysis, with a focus to identify miRNAs that regulate TWIST expression and OS chemoresistance. We provide the first evidence suggesting that miR-33a promotes OS chemoresistance by down-regulating TWIST.
OS is the most common pediatric bone malignancy in the world . As the inclusion rate for adult OS patients was low, we performed this study only in pediatric OS patients. Patients (n = 12) in the discovery cohort were matched on age, sex and tumor stages to reduce the effects of confounders on miRNA profiling between chemoresistant and control OS samples. Patients (n = 70) in the validation cohort were not matched in order to verify the profiling findings in a more generalizable setting. Among the up-regulated miRNAs identified in chemoresistant OS samples in this study, miR-140, miR-215 and miR-221 have been reported to induce human OS chemoresistance [20–22]. Among the down-regulated miRNAs identified in chemoresistant OS samples, miR-451 and miR-15b have been reported to increase chemosensitivity of OS . Thus, our findings were in agreement with previous studies, indicating good reliability of the data.
High expression of TWIST has been detected in several cancers and has been associated with the initial phase of metastatic progression . One recent study reported that TWIST overexpression correlated with disease progression and a poor clinical outcome in OS patients . On the other hand, it has been reported that in homogeneous cohort of OS patients, the TWIST gene was frequently deleted in the tumors at diagnosis, and its haploinsufficiency was significantly correlated with a poorer patient outcome [6, 9]. In addition, two recent studies reported that TWIST could decrease OS cell survival against cisplatin by inhibiting β-catenin signaling and endothelin-1/endothelin A receptor signaling pathways [10, 11], suggesting that TWIST is an important negative regulator in the development of OS chemoresistance. In this study, our in vitro results showed that overexpression and knockdown of TWIST increased and decreased cisplatin-induced OS cell apoptosis, respectively. This was corroborated by our findings that the expression of TWIST in the chemoresistant OS group was significantly lower than that in the control OS group in both the discovery and validation cohorts, which provides further evidence supporting a critical counteracting role of TWIST in the development of OS chemoresistance.
With an aim to identify miRNAs regulating TWIST expression in OS, we found that miR-33a could significantly down-regulate TWIST expression, which was supported by an inverse miRNA-33a/TWIST expression trend in the validation cohort, target-sequence-specific inhibition of TWIST-3′UTR-luciferase reporter activity by miR-33a, and alteration of TWIST expression by overexpression or inhibition of miR-33a in human OS cell lines. Saos-2 and MG-63 cells were employed as OS cell models in this study. Saos-2 cells have a constitutive high expression of miR-33a and low expression of TWIST, while MG-63 cells have a constitutive low expression of miR-33a and high expression of TWIST. This explains why inhibition of miR-33a by antagomir-33a had more pronounced effects on TWIST expression than overexpressing miR-33a in Saos-2 cells. Likewise, overexpressing miR-33a had more pronounced effects on TWIST expression than antagomir-33a treatment in MG-63 cells. The effects of overexpression and inhibition of miR-33a on TWIST expression significantly altered OS cell resistance to cisplatin, a chemotherapeutic agent routinely used in neoadjuvant chemotherapy for OS . In the presence of cisplatin, antagomir-33a significantly enhanced cisplatin-induced apoptosis in both Saos-2 and MG-63 cells, suggesting that inhibition of miR-33a could be a potential new strategy to enhance neoadjuvant chemotherapy for OS. The effects of antagomir-33a was reversed and enhanced by knockdown and overexpression of TWIST, respectively, indicating that miR-33a promotes OS cell resistance to cisplatin by down-regulating TWIST, or antagomir-33a enhances cisplatin-induced OS cell apoptosis by up-regulating TWIST. miR-33a has been shown to regulate genes involved in fatty acid metabolism and insulin signaling . A recent study indicated that miR-33a targets the proto-oncogene Pim-1 and suggested overexpression of miR-33a as an anticancer treatment . However, another study described the down-regulation of tumor suppressor p53 by miR-33 , suggesting a complex and possible context-dependent response to miR-33 manipulations. As p53 is often mutated in OS , it is unlikely that miR-33a promotes OS chemoresistance through down-regulating p53-induced apoptosis. Thus, the enhancing effect of miR-33a on OS chemoresistance via down-regulating TWIST expression is a new function of this miR, and the miR-33a/TWIST signaling could be a novel mechanism involved in development of OS chemoresistance.
There are some limitations of this study:  This study was only performed in pediatric OS patients. Despite that adult OS patients only occupy a small portion of total OS patients, it would still be interesting to verify the findings in adult patients in future studies.  Cisplatin elicits DNA repair mechanisms by crosslinking DNA, which in turn activates apoptosis when repair proves impossible . In this study, we only examined the effect of miR-33a/TWIST signaling on OS cell resistance to cisplatin. It is unclear whether miR-33a/TWIST would impact OS cell resistance to other types of chemotherapy agents. Further studies with more types of chemotherapy agents and OS cell lines would elaborate this issue.
In conclusion, we demonstrate that miR-33a is up-regulated in chemoresistant OS and that the miR-33a level is negatively correlated with the TWIST protein level and the tumor necrosis rate in OS. Our in vitro data indicate that miR-33a promotes OS cell resistance to cisplatin by down-regulating TWIST; on the other hand, inhibition of miR-33a by antagomir-33a enhances cisplatin-induced apoptosis in OS cells by up-regulating TWIST expression. The findings suggest that inhibition of miR-33a/TWIST signaling could be a potential new strategy to enhance neoadjuvant chemotherapy for OS.
This work was supported by Hunan Provincial Natural Science Foundation (grants #10C2613, #11D4175, and #12 E5688), Hunan, P.R. China.
- Ottaviani G, Jaffe N: The epidemiology of osteosarcoma. Pediatric and Adolescent Osteosarcoma. Edited by: Jaffe N. 2009, New York: Springer, 122-136.Google Scholar
- Subbiah V, Kurzrock R: Phase 1 clinical trials for sarcomas: the cutting edge. Curr Opin Oncol. 2011, 23: 352-360. 10.1097/CCO.0b013e3283477a94.View ArticlePubMedGoogle Scholar
- Chou AJ, Gorlick R: Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006, 6: 1075-1085. 10.1586/14737184.108.40.2065.View ArticlePubMedGoogle Scholar
- Uribe-Botero G, Russell WO, Sutow WW, Martin RG: Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54. Am J Clin Pathol. 1977, 67: 427-435.PubMedGoogle Scholar
- Geller DS, Gorlick R: Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2010, 8: 705-718.PubMedGoogle Scholar
- Entz-Werlé N, Lavaux T, Metzger N, Stoetzel C, Lasthaus C, Marec P, Kalifa C, Brugieres L, Pacquement H, Schmitt C, Tabone MD, Gentet JC, Lutz P, Babin A, Oudet P, Gaub MP, Perrin-Schmitt F: Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis. Neoplasia. 2007, 9: 678-688. 10.1593/neo.07367.PubMed CentralView ArticlePubMedGoogle Scholar
- Stoetzel C, Weber B, Bourgeois P, Bolcato-Bellemin AL, Perrin-Schmitt F: Dorso-ventral and rostro-caudal sequential expression of M-twist in the postimplantation murine embryo. Mech Dev. 1995, 51: 251-263. 10.1016/0925-4773(95)00369-X.View ArticlePubMedGoogle Scholar
- El Ghouzzi V, Le Merrer M, Perrin-Schmitt F, Lajeunie E, Benit P, Renier D, Bourgeois P, Bolcato-Bellemin AL, Munnich A, Bonaventure J: Mutations of the TWIST gene in the Saethre-Chotzen syndrome. Nat Genet. 1997, 15: 42-46. 10.1038/ng0197-42.View ArticlePubMedGoogle Scholar
- Le Deley MC, Guinebretière J, Gentet JC, Pacquement H, Pichon F, Marec-Bérard P, Entz-Werlé N, Schmitt C, Brugières L, Vanel D, Dupoüy N, Tabone MD, Kalifa C: SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 2007, 43: 752-761. 10.1016/j.ejca.2006.10.023.View ArticlePubMedGoogle Scholar
- Wu J, Liao Q, He H, Zhong D, Yin K: TWIST interacts with β-catenin signaling on osteosarcoma cell survival against cisplatin. Mol Carcinog. 2012, 10.1002/mc.21991Google Scholar
- Zhou Y, Zang X, Huang Z, Zhang C: TWIST interacts with endothelin-1/endothelin A receptor signaling in osteosarcoma cell survival against cisplatin. Oncol Lett. 2013, 5: 857-861.PubMed CentralPubMedGoogle Scholar
- Ma R, Jiang T, Kang X: Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res. 2012, 31: 38-10.1186/1756-9966-31-38.PubMed CentralView ArticlePubMedGoogle Scholar
- Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, Volinia S, Stein GS, Croce CM, Lian JB, Aqeilan RI: miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res. 2012, 72: 1865-1877. 10.1158/0008-5472.CAN-11-2663.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu X, Chen X, Yu X, Tao Y, Bode AM, Dong Z, Cao Y: Regulation of microRNAs by epigenetics and their interplay involved in cancer. J Exp Clin Cancer Res. 2013, 32: 96-10.1186/1756-9966-32-96.PubMed CentralView ArticlePubMedGoogle Scholar
- Nana-Sinkam SP, Croce CM: MicroRNAs as therapeutic targets in cancer. Transl Res. 2011, 157: 216-225. 10.1016/j.trsl.2011.01.013.View ArticlePubMedGoogle Scholar
- Bacci G, Bertoni F, Longhi A, Ferrari S, Forni C, Biagini R, Bacchini P, Donati D, Manfrini M, Bernini G, Lari S: Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer. 2003, 97: 3068-3075. 10.1002/cncr.11456.View ArticlePubMedGoogle Scholar
- Matsuo N, Shiraha H, Fujik T, Takaoka N, Ueda N, Tanaka S, Nishina S, Nakanishi Y, Uemura M, Takaki A, Nakamura S, Kobayashi Y, Nouso K, Yagi T, Yamamoto K: Twist expression promotes migration and invasion in hepatocellular carcinoma. BMC Cancer. 2009, 9: 240-10.1186/1471-2407-9-240.PubMed CentralView ArticlePubMedGoogle Scholar
- Voorhoeve PM, Le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, Van Duijse J, Drost J, Griekspoor A, Zlotorynski E, Yabuta N, De Vita G, Nojima H, Looijenga LH, Agami R: A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 2006, 124: 1169-1181. 10.1016/j.cell.2006.02.037.View ArticlePubMedGoogle Scholar
- Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C (T) method. Nat Protoc. 2008, 3: 1101-1108. 10.1038/nprot.2008.73.View ArticlePubMedGoogle Scholar
- Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M, Fodstad O, Ju J: Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene. 2009, 28: 4065-4074. 10.1038/onc.2009.274.PubMed CentralView ArticlePubMedGoogle Scholar
- Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M, Ju J: Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer. 2010, 9: 96-10.1186/1476-4598-9-96.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhao G, Cai C, Yang T, Qiu X, Liao B, Li W, Ji Z, Zhao J, Zhao H, Guo M, Ma Q, Xiao C, Fan Q, Ma B: MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One. 2013, 8: e53906-10.1371/journal.pone.0053906.PubMed CentralView ArticlePubMedGoogle Scholar
- Yin K, Liao Q, He H, Zhong D: Prognostic value of Twist and E-cadherin in patients with osteosarcoma. Med Oncol. 2012, 29: 3449-3455. 10.1007/s12032-012-0317-6.View ArticlePubMedGoogle Scholar
- Dávalos A, Goedeke L, Smibert P, Ramírez CM, Warrier NP, Andreo U, Cirera-Salinas D, Rayner K, Suresh U, Pastor-Pareja JC, Esplugues E, Fisher EA, Penalva LO, Moore KJ, Suárez Y, Lai EC, Fernández-Hernando C: miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci USA. 2011, 108: 9232-9237. 10.1073/pnas.1102281108.PubMed CentralView ArticlePubMedGoogle Scholar
- Thomas M, Lange-Grunweller K, Weirauch U, Gutsch D, Aigner A, Grunweller A, Hartmann RK: The protooncogene Pim-1 is a target of miR-33a. Oncogene. 2012, 31: 918-928. 10.1038/onc.2011.278.View ArticlePubMedGoogle Scholar
- Herrera-Merchan A, Cerrato C, Luengo G, Dominguez O, Piris MA, Serrano M, Gonzalez S: miR-33-Mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle. 2010, 9: 3277-3285.View ArticlePubMedGoogle Scholar
- Kanamori M, Sano A, Yasuda T, Hori T, Suzuki K: Array-based comparative genomic hybridization for genomic-wide screening of DNA copy number alterations in aggressive bone tumors. J Exp Clin Cancer Res. 2012, 31: 100-10.1186/1756-9966-31-100.PubMed CentralView ArticlePubMedGoogle Scholar
- Rosenberg B, Vancamp L, Trosko JE, Mansour VH: Platinum compounds: a new class of potent antitumour agents. Nature. 1969, 222: 385-386. 10.1038/222385a0.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.